Legend Biotech LEGN underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 10 | 5 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 5 | 1 | 0 | 0 | 0 |
| 2M Ago | 3 | 1 | 0 | 0 | 0 |
| 3M Ago | 2 | 2 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $80.67, a high estimate of $90.00, and a low estimate of $60.00. A decline of 0.81% from the prior average price target is evident in the current average.
Deciphering Analyst Ratings: An In-Depth Analysis
A comprehensive examination of how financial experts perceive Legend Biotech is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Leonid Timashev | RBC Capital | Maintains | Outperform | $86.00 | $86.00 |
| Edward Tenthoff | Piper Sandler | Maintains | Overweight | $90.00 | $90.00 |
| Asthika Goonewardene | Truist Securities | Announces | Buy | $88.00 | - |
| Mitchell Kapoor | HC Wainwright & Co. | Maintains | Buy | $73.00 | $73.00 |
| Mitchell Kapoor | HC Wainwright & Co. | Maintains | Buy | $73.00 | $73.00 |
| Mitchell Kapoor | HC Wainwright & Co. | Lowers | Buy | $73.00 | $86.00 |
| James Shin | Deutsche Bank | Announces | Buy | $60.00 | - |
| Leonid Timashev | RBC Capital | Raises | Outperform | $86.00 | $85.00 |
| Mitchell Kapoor | HC Wainwright & Co. | Lowers | Buy | $86.00 | $87.00 |
| Mitchell Kapoor | HC Wainwright & Co. | Maintains | Buy | $87.00 | $87.00 |
| Mitchell Kapoor | HC Wainwright & Co. | Maintains | Buy | $87.00 | - |
| George Farmer | Scotiabank | Maintains | Sector Outperform | $65.00 | $65.00 |
| Mitchell Kapoor | HC Wainwright & Co. | Maintains | Buy | $87.00 | - |
| Rick Bienkowski | Cantor Fitzgerald | Announces | Overweight | $82.00 | - |
| Mitchell Kapoor | HC Wainwright & Co. | Maintains | Buy | $87.00 | - |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Legend Biotech. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Legend Biotech compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Legend Biotech's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Legend Biotech's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Legend Biotech analyst ratings.
About Legend Biotech
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Legend Biotech's Financial Performance
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Legend Biotech's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 158.67%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Legend Biotech's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -63.62%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Legend Biotech's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -4.95%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Legend Biotech's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -3.3%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Legend Biotech's debt-to-equity ratio is below the industry average at 0.29, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyst Ratings: Simplified
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
